BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) has appointed Alex Hughes as its chief financial officer, replacing Glyn Barker, who will leave the company at the end of the month.
Hughes boasts 10 years of experience in senior finance and operational positions, having previously worked at Argent Energy and Luxfer MEL Technologies. Most recently, he served as finance director at Instil Bio Inc, a US biotechnology group.
BiVictriX chief executive Tiffany Thorn said: "We look forward to working with Alex as we enter this new period of growth following our recent positive preclinical safety results of BVX001.
"I am confident that his extensive financial experience will help guide the company, as we continue to make great progress in the development of our urgently-needed next-generation therapeutics.
"I would personally like to thank Glyn for his dedication and much-valued support during his time with us."
The emerging company, which is listed on AIM under the ticker BVX, develops cancer therapies that aim to improve both tolerability and anti-cancer activity. Its recent preclinical safety results from lead candidate BVX001 were positive.